StockNews.com Downgrades Fortress Biotech (NASDAQ:FBIO) to Sell

Fortress Biotech (NASDAQ:FBIOGet Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Wednesday.

Several other research analysts have also recently issued reports on FBIO. Alliance Global Partners assumed coverage on shares of Fortress Biotech in a report on Tuesday, March 19th. They set a “buy” rating and a $5.00 target price for the company. Roth Mkm reissued a “buy” rating and set a $10.00 target price on shares of Fortress Biotech in a report on Thursday, May 16th.

Get Our Latest Stock Report on FBIO

Fortress Biotech Trading Down 1.0 %

NASDAQ:FBIO opened at $1.97 on Wednesday. Fortress Biotech has a 12 month low of $1.24 and a 12 month high of $10.65. The firm has a fifty day simple moving average of $1.81 and a 200-day simple moving average of $2.07. The company has a current ratio of 1.33, a quick ratio of 1.21 and a debt-to-equity ratio of 38.42. The company has a market capitalization of $39.24 million, a P/E ratio of -0.32 and a beta of 1.68.

Fortress Biotech (NASDAQ:FBIOGet Free Report) last posted its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($2.03) by $1.00. Fortress Biotech had a negative net margin of 69.13% and a negative return on equity of 770.86%. The business had revenue of $13.03 million during the quarter, compared to the consensus estimate of $14.33 million. On average, equities research analysts anticipate that Fortress Biotech will post -5.07 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FBIO. Virtu Financial LLC purchased a new position in Fortress Biotech in the first quarter valued at $31,000. PFG Investments LLC purchased a new position in Fortress Biotech in the first quarter valued at $33,000. Gladstone Institutional Advisory LLC acquired a new stake in shares of Fortress Biotech in the fourth quarter valued at about $36,000. Wealth Management Partners LLC acquired a new stake in shares of Fortress Biotech in the fourth quarter valued at about $60,000. Finally, Choreo LLC acquired a new position in Fortress Biotech during the fourth quarter worth about $109,000. Hedge funds and other institutional investors own 96.51% of the company’s stock.

About Fortress Biotech

(Get Free Report)

Fortress Biotech, Inc, a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne.

Featured Articles

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.